CreatorsPublishersAdvertisers
View more in
Health

First patient dosed in optogenetic gene therapy trial

ophthalmologytimes.com
 2021-07-19

Cover picture for the articleNanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells. The first patient has been dosed in Nanoscope Therapeutics Inc.’s Phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with retinitis pigmentosa (RP).

www.ophthalmologytimes.com

Comments / 0

Comments / 0